<DOC>
	<DOCNO>NCT00217646</DOCNO>
	<brief_summary>This randomized phase I trial study side effect best dose two different schedule sorafenib treat patient refractory relapse acute leukemia , myelodysplastic syndrome , blastic phase chronic myelogenous leukemia . Sorafenib may stop growth cancer cell block enzymes need cell growth block blood flow cancer .</brief_summary>
	<brief_title>Sorafenib Treating Patients With Refractory Relapsed Acute Leukemia , Myelodysplastic Syndromes , Blastic Phase Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine maximum tolerate dose sorafenib administer two different schedule patient refractory relapse acute leukemia , myelodysplastic syndrome , blastic phase chronic myelogenous leukemia . II . Determine dose-limiting toxicity drug patient . SECONDARY OBJECTIVES : I . Determine clinical activity drug patient . II . Determine biologic effect drug patient . OUTLINE : This randomize , dose-escalation phase I study . Patients randomize 1 2 treatment arm . Arm I : Patients receive oral sorafenib twice daily day 1-5 , 8-12 , 15-19 . Arm II : Patients receive oral sorafenib twice daily day 1-14 . In arm , treatment repeat every 21 day 6 month absence disease progression unacceptable toxicity . Patients achieve complete remission partial remission 6 month may continue therapy discretion principal investigator . In arm , cohort 3-6 patient receive escalate dos sorafenib maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Up 10 patient treated MTD .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Monocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Hypereosinophilic Syndrome</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Leukemia , Promyelocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Erythroblastic , Acute</mesh_term>
	<mesh_term>Leukemia , Megakaryoblastic , Acute</mesh_term>
	<mesh_term>Leukemia , Eosinophilic , Acute</mesh_term>
	<mesh_term>Leukemia , Basophilic , Acute</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Diagnosis 1 follow : Acute myeloid leukemia ( Acute promyelocytic leukemia ( M3 ) allow provide patient fail prior therapy tretinoin arsenic alone combination ) ; Acute lymphoblastic leukemia ; Myelodysplastic syndrome ; Blastic phase chronic myelogenous leukemia ( Failed OR intolerant imatinib mesylate ) Must fail prior therapy &gt; = 1 cytotoxic biologictargeted agent ( e.g. , hypomethylating agent , farnesyl transferase inhibitor , thalidomide , tyrosine kinase inhibitor ) ; Any number prior regimen allow Performance status : ECOG 01 ALT = &lt; 2.5 time upper limit normal Bilirubin = &lt; 1.5 mg/dL Creatinine = &lt; 2.0 mg/dL OR Creatinine clearance &gt; = 60 mL/min Fertile patient must use effective contraception No psychiatric illness social situation would preclude study compliance Prior bone marrow transplantation allow At least 2 week since prior cytotoxic agent OR least 5 halflives noncytotoxic agent absence rapidly progress disease At least 24 hour since prior hydrea control peripheral blood leukemia cell count Hydroxyurea allow 72 hour start therapy sorafenib No persistent , chronic , clinically significant toxicity &gt; grade 1 prior chemotherapy Cytopenias secondary multilineage bone marrow failure allow Ineligible willing undergo allogeneic stem cell transplantation OR donor available Absolute blast count= &lt; 20,000/mm^3 unless patient document fmslike tyrosine kinase 3 internal tandem duplication No evidence bleed diathesis ( except due low platelet associate primary disease ) No New York Heart Association class III IV congestive heart failure No uncontrolled hypertension ( i.e. , sustain systolic blood pressure [ BP ] &gt; = 150 mm Hg diastolic BP &gt; = 90 mm Hg ) No unstable angina pectoris No symptomatic cardiac arrhythmia require respond medical intervention Not pregnant nursing No history allergic reaction attribute compound similar chemical biological composition study drug No swallowing dysfunction would impede oral ingestion tablets No active uncontrolled infection No uncontrolled illness No prior sorafenib No concurrent investigational commercial agent , except standard intrathecal chemotherapy treatment isolate CNS leukemic involvement No concurrent anticancer agents No concurrent combination antiretroviral therapy HIVpositive patient No concurrent therapeutic anticoagulation ( Concurrent prophylactic anticoagulation [ i.e. , lowdose warfarin , catheter flush heparin ] venous arterial access device allow ) No concurrent cytochrome P450 enzymeinducing antiepileptic agent , include , limited , follow : Phenytoin ; Carbamazepine ; Phenobarbital ; Rifampin No concurrent Hypericum perforatum ( St. John 's wort )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>